Terns Pharmaceuticals: Truist sees enormous market potential and an attractive risk-reward profile for the pipeline!
Reading Time: 2 minutes
Currently, one of the standout names on the analysts' Top-10 price target list is Terns Pharmaceuticals (TERN) . The biotechnology company specializes in developing small-molecule candidates for treating serious diseases such as oncology and obesity. The central event in the fall months was the intense focus on the main candidate TERN-701, an allosteric BCR-ABL inhibitor being developed for the treatment of chronic myeloid leukemia (CML). On September 3, 2025, Terns Pharmaceuticals held an important investor educational webinar about TERN-701. This...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
